All News

Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.

A phase 2 study is examining Keytruda in combination with two other agents for treatment of ovarian cancer.

Cooling caps to prevent chemothreapy-related hair loss are gaining popularity in the United States.

Are electronic cigarettes less harmful than traditional cigarettes? A upcoming study is looking to find out.

Recent-onset diabetes can lead to poorer outcomes in pancreatic cancer, according to a recent study.

A week of surfing at cancer camp.

A recently launched clinical trial is exploring a new agent to treat patients with advanced, recurrent, platinum-resistant ovarian cancer.

The House of Representatives just passed the 21st Century Cures Act, providing over $6 billion for health initiatives.

Keytruda was granted a priority review to a supplemental biologics license application (sBLA) to treat a subset of patients with classical Hodgkin lymphoma.

With the addition of PARP inhibitors, as well as new agents on the horizon, the treatment landscape of gynecologic cancers is progressing.

I actively encourage all my clients experiencing life-altering stressors to trick the mind using the art of reframing.

Six-year breast cancer survivor is still unhappy with brain fog, even this far out from chemotherapy treatments.

The combination of Opdivo and Yervoy is showing promise in the treatment of bladder cancer, according to a recent study.

A combination of topical drugs may reduce lesions that eventually grow into cancer, according to a recent study.

The National LGBT Cancer Network is making cancer screenings more available to a high-risk, underserved population.

Some of the leading nonprofits in the field are teaming together to improve the lives of patients with lung cancer.

In the future, entrectinib may play an increasing role in the treatment of brain tumors, as well as other cancers.

A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.

Immunotherapy continues to advance in melanoma and other solid tumor types as new combinations and biomarkers are being explored.

I really don't understand why some of us bear heavier burdens than others....

Two nonprofits teamed together to make a comprehensive online registry for patients and survivors of lung cancer.

A recent study looked at the relationship between obesity, MGUS and multiple myeloma.

Immunotherapy's role for treating sarcoma is being cemented as more agents and targets are identified.

We all deal with pain. For some of us, it is chronic, but we can't give up. Pain can be a tricky partner to walk along side and is different for everyone. For me, I must face it. I must try to heal it, and I must try to take steps forward, no matter how tiny they may be.

When it comes to employment and insurance after a cancer diagnosis, it is important to read the fine print.

Keytruda may be a viable treatment option for patients with advanced microsatellite instability-high cancer in the future.

Ibrance use will continue to grow for patients with ER-positive, HER2-negative metastatic breast cancer, Richard Finn, M.D., says.